Natalizumab for relapsing-remitting multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Natalizumab in relapsing-remitting multiple sclerosis.
Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease activity and reducing the risk of disability progession in RRMS, and the risk of a serious adverse event (progressive multifocal leukoencephalopathy [PML]), natalizumab was indicated in active RRMS, mostly as a sec...
متن کاملNatalizumab: A new treatment for relapsing remitting multiple sclerosis
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to alpha(4)beta(1)-integrin. In a Phase 3 trial, 2 years of natalizumab monotherapy reduced the mean annualized relapse rate (ARR) by 68% compared with placebo (p < 0.001) and the risk of sustained disability progression was reduced by 42% in the nataliz...
متن کاملNatalizumab for relapsing multiple sclerosis.
To the Editor: As Ropper pointed out in his editorial (March 2 issue),1 the three articles on the use of natalizumab in that issue of the Journal are pivotal, but his conclusion that natalizumab is “a potent treatment for multiple sclerosis” may be too sanguine. The similar entry criteria, treatment, and methods of analysis permit clinically useful conclusions to be drawn from the placebocontro...
متن کاملAlemtuzumab for relapsing-remitting multiple sclerosis.
In the past 10 years, the treatment options for patients with relapsing-remitting multiple sclerosis (RRMS) underwent some major changes. After relying on injectable interferon-beta preparations for quite some time, the advent of the first monoclonal antibody, natalizumab, followed by the first oral drug, fingolimod, improved the outcome of these patients and the possibilities to treat them mor...
متن کاملDimethyl fumarate for relapsing-remitting multiple sclerosis.
For many years the only drugs licensed for the treatment of multiple sclerosis (MS) were administered by injection (interferon beta, glatiramer and ▼natalizumab). Recently, three oral drugs have become available. We have previously reviewed the use of ▼fingolimod for highly active relapsing-remitting MS1 and ▼teriflunomide for the management of relapsing-remitting MS in adults.2 Here, we review...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurología (English Edition)
سال: 2011
ISSN: 2173-5808
DOI: 10.1016/s2173-5808(11)70082-7